NCT07513285Phase 2Recruiting

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Study sponsor: Acurx Pharmaceuticals Inc. · ACXP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09-29Estimated
Enrollment · participants20Estimated
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source